Tatum van Maanen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Tatum van Maanen has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Antonios Daletzakis
Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands
1 shared publicationBritt B. M. Suelmann
Department of Medical Oncology, University Medical Center of Groningen, University of Groningen, Groningen, The Netherlands
1 shared publicationCheryl P. Bruijnen
Department of Medical Oncology, University Medical Center of Utrecht, University of Utrecht, Utrecht, The Netherlands
1 shared publicationCindy M. J. Hollander
Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
1 shared publicationDaniel J. Vis
Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands
1 shared publicationHamza Ali
Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 17 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial
New therapeutic strategies for patients with therapy-refractory metastatic urothelial carcinoma (mUC) are still needed. In the phase I-II ICRA trial, a multicenter, open-label, phase Ib-II clinical trial (NCT03871036), we evaluated whether paclitaxel plus tremelimumab, with or without durvalumab, could induce a tumor response in mUC following platinum chemotherapy and immune checkpoint inhibition (ICI). Patients were randomized between three arms: A (n = 20) paclitaxel plus T750mg; B (n = 12) paclitaxel plus T300mg plus D1500mg; C (n = 12) T750mg. The primary outcome, objective response rate, was met with 26% in arm A (88% CI = [14,36%]) versus 17% (88% CI = [3,42%]) in arm B and 8% (88% CI = [0.3,33%]) in arm C. Secondary outcomes included safety, duration of response and survival. Grade 3-4 treatment-related adverse events occurred in (A) 45%, (B) 75%, and (C) 25% of patients. Murine experiments showed attenuated tumor outgrowth for paclitaxel plus anti-CTLA-4 compared to monotherapy with either agent. Transcriptomic analyses showed upregulation of inflammation signatures in on-treatment tumor tissue biopsies. This study demonstrated encouraging antitumor activity in therapy-refractory mUC treated with paclitaxel plus high-dose anti-CTLA-4 and suggests immune induction may still be possible after failure to anti-PD-(L)1 therapy.
- 17 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial
New therapeutic strategies for patients with therapy-refractory metastatic urothelial carcinoma (mUC) are still needed. In the phase I-II ICRA trial, a multicenter, open-label, phase Ib-II clinical trial (NCT03871036), we evaluated whether paclitaxel plus tremelimumab, with or without durvalumab, could induce a tumor response in mUC following platinum chemotherapy and immune checkpoint inhibition (ICI). Patients were randomized between three arms: A (n = 20) paclitaxel plus T750mg; B (n = 12) paclitaxel plus T300mg plus D1500mg; C (n = 12) T750mg. The primary outcome, objective response rate, was met with 26% in arm A (88% CI = [14,36%]) versus 17% (88% CI = [3,42%]) in arm B and 8% (88% CI = [0.3,33%]) in arm C. Secondary outcomes included safety, duration of response and survival. Grade 3-4 treatment-related adverse events occurred in (A) 45%, (B) 75%, and (C) 25% of patients. Murine experiments showed attenuated tumor outgrowth for paclitaxel plus anti-CTLA-4 compared to monotherapy with either agent. Transcriptomic analyses showed upregulation of inflammation signatures in on-treatment tumor tissue biopsies. This study demonstrated encouraging antitumor activity in therapy-refractory mUC treated with paclitaxel plus high-dose anti-CTLA-4 and suggests immune induction may still be possible after failure to anti-PD-(L)1 therapy.